Response Tailored Protocol Versus the Fixed 12 Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial-Reference-Cited by-同舟云学术

Response Tailored Protocol Versus the Fixed 12 Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial

Published:2017-07 Issue: Volume:21 Page:182-187
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Yakoot Mostafa,Abdo Alaa M.,Abdel-Rehim Siham,Helmy Sherine

Funder

Abbass Helmy Charity

Pharco

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference12 articles.

1. Daclatasvir-based treatment regimens for hepatitis C virus infection: a systematic review and meta-analysis;Alavian;Hepat. Mon.,2016

2. Realworld effectiveness of ledipasvir/sofosbuvir (LDV/SOF) in treatment-experienced cirrhotic genotype 1 patients with chronic hepatitis C: a comparative analysis of Gilead sponsored trials with 4 real-world cohorts;Curry;J. Hepatol.,2016

3. HCV Italian resistance network study group. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies;Di Maio;Liver Int.,2017

4. Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection;D'Offizi;New Microbiol.,2017

5. EASL recommendations on treatment of hepatitis C 2016;European Association for the Study of the Liver;J. Hepatol.,2017

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of 8-Week Daclatasvir-Sofosbuvir Regimen in Chronic Hepatitis C: A Systematic Review and Meta-Analysis;2024-09-12

2. Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study;eLife;2023-01-09

3. Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for Hepatitis C: a single arm mechanistic pilot study;2022-08-17

4. Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT;Efficacy and Mechanism Evaluation;2021-10

5. Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C;Wellcome Open Research;2021-07-29